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Abstract: Many medications are prescribed and administered PRN (pro re nata, as needed). However,
there are few integrative reviews to inform PRN psychotropic medication use in long-term care
facilities and nursing or care homes. Accordingly, this integrative systematic review aimed to
improve our understanding of PRN medicines management with a focus on psychotropic medications
(antipsychotics, sedatives, anxiolytics, and hypnotics) in long-term care settings. Keywords relating
to PRN in English, Norwegian, and Spanish were used, and articles published between 2009 and 2019
were retrieved. Based on the inclusion criteria, eight articles were used for data analysis and synthesis.
This review offers a description of PRN prescription and administration of psychotropic medications
in long-term care. Variations were observed in the management of PRN psychotropic medications
based on residents’ underlying health conditions and needs, duration of use, and changes between
medications and doses. Neither the reasons for PRN prescription and administration nor the steps
taken to identify and manage any associated adverse reactions or adverse drug events were reported.
Further initiatives are needed to improve PRN medicines management to explore factors that affect
PRN prescription and administration and to develop appropriate PRN guidelines to prevent harm
and improve the safety of people living in long-term care facilities.
Keywords: pro re nata; PRN; medicines management; nurse; patient safety; psychotropic medications;
long-term care setting
1. Introduction
PRN stands for “pro re nata,” and indicates authorising nurses to administer medications
according to patients’ requests and nurses’ discretion. PRN is categorized as unscheduled medication
administration either alone or in addition to routine/regular prescriptions [1]. It is frequently used
for medications prescribed by physicians and administered based on nurses’ judgements of patients’
needs [2–7], but PRN medications are sometimes self-administered or given by family or informal
caregivers [2]. PRN is commonly used to prescribe medications required in particular conditions, such
as a complement to regularly scheduled medications [8]. It empowers nurses and patients and gives
them more flexibility for relieving unpleasant physical and mental symptoms [2,9]. Moreover, active
involvement in decision-making regarding patient care, including medicines management, can be
considered to increase professional autonomy, with the potential to increase the sense of self-worth and
accomplishment in practice [10]. However, PRN medication decision-making for nurses is complex,
and is influenced by pharmacotherapeutic competencies and skills, patient and family involvement,
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and organizational routines [11,12]. Decision-making is a key skill for many healthcare professionals
and is important to ensure patient safety [13].
PRN prescription and administration is commonly used for psychotropic and psycholeptics
medications, including antipsychotics, neuroleptics, anxiolytics, sedatives, and hypnotics [6,8,9,14–18],
analgesics [6,12,14,19–21], gastro-intestinal preparations [12,14], and other physical and psychological
symptoms [2]. Benefits of PRN administration to patients are noted [2,9], but the use of PRN
psychotropic medications has been linked to an increased risk of falls [22–24], infection, or
dehydration [24]. PRN medication is associated with dementia diagnosis, older age, polypharmacy,
and a longer length of stay in nursing homes [8,25]. Additionally, higher rates of PRN administration
have been associated with high dependency in daily living activities [25], individual care homes [12,26],
polypharmacy, increased risk of dependence, overdose, and overuse of medications [4,8,24,27], but
more exploration is needed [25,26]. PRN can be linked to administration without the patient’s consent
or full disclosure of relevant information about PRN medications, particularly to patients suffering
from cognitive impairments [3,28]. While potentially inappropriate use of PRN medications [24]
has been reported, one study of PRN medication administration based on medication charts in
residential aged care services has shown that rates of administration of PRN medications are lower
than anticipated [12]. However, this might have been attributed to a lack of documentation, poor
concordance between written notes and verbal reports [16,29], and the use of self-report and phone
interviews to assess PRN medication use [30]. Since then, the use of electronic health records in hospitals
has increased the accuracy of data collection on the quantity of PRN medication, its prescription, and
its administration [16].
PRN medicine use in long-term care settings has long been considered integral to medicines
management systems. However, there are few systematic reviews of PRN medicines management in
long-term care settings, and those available provide an overall description of PRN only in nursing
homes and without a focus on psychotropics medicines [25], the class of medications most commonly
administered to residents as PRN. We did not identify reviews of PRN psychotropic medication use
in long-term care settings. Therefore, the present systematic review aims to address this gap, and
improve understanding of PRN medicines management.
2. Materials and Methods
2.1. Design of the Study
This integrated systematic review considered both qualitative and quantitative papers [31–33]
on PRN medicines management with a focus on psychotropic medications in long-term care settings.
The integrative approach provided the opportunity to incorporate individuals’ understanding gained
from qualitative studies with statistical data and present a more comprehensive image of the study
phenomenon [34].
2.2. Search Strategy and Data Collection
The authors’ experiences in the field of medicines management and a pilot search in international
general and specialized databases helped to identify appropriate keywords. Boolean search methods
were used to identify articles on PRN medicines management of psychotropic medications in
long-term care settings using the following terms: “PRN” (pro re nata) OR “as needed” OR “as
required” AND psychotropic/s OR antipsychotic OR neuroleptic OR anxiolytics OR sedatives OR
psycholeptic/s OR anxiolytics OR hypnotics OR risperidone OR haloperidol OR lorazepam OR
temazepam OR phenothiazines AND “long-term” OR home OR “home health nursing” OR “home
nursing.” The above-mentioned keywords were translated to Norwegian and Spanish, and a similar
systematic search in Nordic and Spanish scientific databases was conducted. Online databases (PubMed
[including Medline], Scopus, Cinahl, Cochrane library, Norart, SweMed, IBECS, Cuiden, and Medes)
were searched to retrieved articles published from 2009 to 2019 in scientific journals. Inclusion criteria
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were a focus on PRN prescription and administration for psychotropic medications in long-term care
settings, and publication in peer-reviewed journals.
2.3. Systematic Review and Quality Appraisal
The search process was performed independently by the authors (MV, MFV, and HS), but they
held online discussions to share their results and make decisions on the further steps of the review.
The search process identified 1594 articles (Table 1).
Table 1. Results of the systematic review.
Database Total in EachDatabase
Title
Selection
Abstract
Selection
Full-Text
Appraisal
PubMed (including Medline) 618 4 2 2
Scopus 105 29 5 5
Cochrane library 326 1 0 0
Cinahl 142 5 0 0
Norart (Nordic) 2 2 1 1
SweMed+ (Nordic) 3 2 0 0
IBECS (Spanish) 5 0 0 0
Cuiden (Spanish) 194 2 0 0
Medes (Spanish) 199 9 0 0
Manual search/backtracking references 0 0 0 0
Total 1594 54 8 8
A pre-piloted data extraction table was used to extract the studies’ core details in terms of general
characteristics of studies, methods, sample, settings, and relevant results. Title readings, deletion of
duplicates, and selection of relevant studies to the review topic led to 54 articles that were shared
between the authors to ensure their suitability based on mutual agreements for inclusion in the next
review step. In addition, a manual search was conducted in the more well known journals in the
field of pharmacy, caring science, and medicines management, and no more studies were identified.
Abstracts were read by each author. Those with a possible focus on PRN medicines management
and the use of psychotropic medications in long-term care settings were selected (n = 8). The full
texts of these 8 articles were obtained from Norwegian and UK libraries. They were assessed for
relevance and focus on the study topic, and all 8 were retained. To improve the search coverage, gray
literature and cross-references from bibliographies were reviewed for additional studies, and a manual
search was performed in the reference lists of the 8 studies, and no more articles were identified.
Therefore, the selected articles (n = 8) were appraised in terms of methodological transparency and
soundness through the Enhancing the QUAlity and Transparency of Health Research (EQUATOR)
tools. Accordingly, appraisal tools appropriate to each study’s methodology (including STROBE [for
cross-sectional, observational, and cohort studies] and COREQ [for qualitative studies]) were used to
evaluate the eligibility of each article for inclusion in data analysis in terms of research framework,
findings, and conclusion [35]. Since items of the quality appraisal tools for making a decision for an
article’s inclusion did not have an equal weight, no scoring system was used. Therefore, discussions
on the importance and quality of each article were held between researchers to reach an agreement on
the selection of articles for data analysis and synthesis. The quality appraisal led to no exclusion of
articles. Table 2 summarises the characteristics of the selected articles for inclusion in data analysis
and synthesis.
The following schematic diagram illustrates the inclusion criteria of reporting items for systematic
review and is based on the meta-analysis (PRISMA) statement [36] (Figure 1).
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Table 2. Papers selected for data analysis and synthesis.
Authors/Year Country Objective(s) Method Focus of Data Collection Setting and Sample Demographic Data
Snowdon et al. 2011 [37] Australia
To understand and
compare the patterns of
psychotropic
medications use in
nursing homes.
A cross-sectional survey
Comparison of the patterns of
psychotropic medication, using
data from surveys from 1993,
1998, 2003, and 2009. Details of
current prescription of
medications during the last 14
days or since initiation of regular
or PRN medication were
recorded. Surveys reported the
rate of PRN prescription and
administration in the last 28 days.
The administration of PRN
medications at least 25 out of 28
days was considered regular
medication use.
Number of nursing
homes and percentage of
their participation in the
study were as follows:
46 (98%), 38 (97%), 51
(100%), and 44 (92%), in
years 1993, 1998, 2003,
and 2009, respectively.
Mean number of
residents: 52.5, 52.0, 60.6,
and 56.0, respectively.
Percentages of 36% (n =
895, mean 78.7 years, SD
= 12.1) and 64% (n =
1570, mean 84.2 years,
SD = 9.6) were male and
female, respectively. No
information of their
diagnosis was available.
Carder, 2012 [38] USA
To identify if staff who
were not registered
nurses administered
PRN medications to
residents with dementia.
The qualitative analysis
of interviews and
medication record
reviews
How is a decision on
administering PRN medications
to residents with dementia
made? PRN administration staff
were observed for 6 consecutive
days, 16 h per day, including 72
scheduled medication rounds.
Sixteen interviews were
completed.
Sixteen unlicensed staff
members supervised by
registered nurses
working at three assisted
living settings with all 47
residents in urban and
suburban areas.
Residents were mostly
female. The mean age of
staff was 38 years (SD =
8.3 years) and were
mainly female (75%).
Their job experience
ranged 4 months to 8
years.
Rønningen et al., 2013
[39] Norway
To document prescribing
and administration of
PRN medication in one
nursing home, and to
investigate how often,
and how, the positive
and negative effects of
prescribed PRN
medication
are documented.
A cross-sectional survey
of documentation of
PRN medications
PRN prescription and
administration prevalence.
Description of documentation of
PRN medication effects
(beneficial and harmful) were
documented in terms of quantity
and quality.
PRN medicines
management was
documented and
described for 108
patients in one nursing
home over 15 weeks.
Mean age of residents
was 84.5 years (SD = 9.4
years). They were
mostly female (60.2%).
No data on staff were
provided.
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Table 2. Cont.
Authors/Year Country Objective(s) Method Focus of Data Collection Setting and Sample Demographic Data
Voyer et al., 2015 [40] Canada
To identify behavioural
and psychological
symptoms in dementia
that were associated
with PRN antipsychotic
medicine prescription
and administration.
A secondary analysis on
a prospective,
observational, multisite
cohort
Association between behavioural
and psychological symptoms of
dementia with PRN
antipsychotic medicine use.
Medication records of regular
and PRN use of medication were
reviewed. Atypical antipsychotic
agents (risperidone (Risperdal®),
olanzapine (Zyprexa®), and
quetiapine (Seroquel®), and
typical antipsychotic agents
(haloperidol (Haldol®) were
used. Prescription and
administration of PRN
antipsychotic agents during 7
days before the monthly
assessment of behavioural and
psychological symptoms of
dementia assessments were
considered.
A total of 146 nursing
home residents from 7
settings. Subjects aged
≥65 years were included.
Those without dementia,
cognitive impairment, or
behavioural and
psychological symptoms
were excluded.
Participants had a mean
age of 85.6 years (SD = 7
years) and were mostly
female (58.9%). They
mainly were diagnosed
with dementia (89.7%).
Of 129 nurses, 76.7%
were registered nurses
and 90.7% were female.
Their experience in
geriatric wards was
mainly greater than 10
years (72%).
Dörks et al., 2016 [41] Germany
To examine the
characteristics and
potential predictors of
PRN prescription and
administration in
nursing homes.
A multicentre survey
Investigation of characteristics
and potential predictors of PRN
medicine prescription and
administration in nursing homes.
A total of 852 residents
in 21 nursing homes
organised by different
institutions.
Their mean age was 83.5
years (SD = 10.5) and
76.5% were female.
Their mean length of
stay was 3.2 years (SD =
3.4).
Allers et al., 2017 [42] Germany
To compare the use of
antipsychotic
medications in residents
with and without
dementia.
A cross-sectional survey
Assessment of the prevalence of
antipsychotic medicine use and
exploration of factors affecting
their prescription. While data on
all prescribed medications were
collected from the residents’
medication schedules,
antipsychotics prescribed as
scheduled medication and on a
PRN basis were studied and
prescriptions of scheduled and
PRN medication were compared.
All residents (n = 852)
from 21 nursing homes
without any exclusion
criteria.
A percentage of 57.7% of
the residents were
diagnosed with
dementia and their
mean age was higher
than those without it
(84.9 vs. 81.4 years, but
no standard deviations
were presented). About
three quarters of the
residents were female
and those with dementia
were more commonly
severely care-dependent
(32.8 vs. 16.4%).
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Table 2. Cont.
Authors/Year Country Objective(s) Method Focus of Data Collection Setting and Sample Demographic Data
Westbury et al., 2018 [43] Australia
To study the impact of
an interdisciplinary
intervention on the
prescription of
antipsychotics and
benzodiazepines in older
people’s residential care
facilities.
A longitudinal study
with comparisons over
time
Investigation of the impact of an
educational consultation
intervention on the use of
antipsychotics and
benzodiazepines over 6 months.
It assessed the possibility of
substitution of medications
prescribed regularly. The
multi-strategic programme
comprised: auditing
psychotropic medication, staff
education, and case reviews by
the physician, pharmacist, and
nurse at the beginning of the
programme and at 3 and
6 months.
A national-level sample
consisting of 150 older
people’s residential care
facilities hosting 12,157
people.
The residents’ mean age
was 85.8 years (SD = 8.6).
Westbury et al., 2019 [44] Australia
To analyse the use of
psychotropics in a
national sample of
residential aged care
facilities.
A retrospective cohort
Analysis of psychotropic use in a
large national sample of
residential aged care facility
residents, derived from a project
to promote the appropriate use
of antipsychotics and
benzodiazepines. A
multi-strategic interdisciplinary
intervention was devised
consisting of a 6-month
programme with cycles of audits,
education, and a review of
sedatives. Prescribing data were
extracted via a
custom-made website.
A large national-level
sample of 150 residential
aged care facilities
consisting of
11,368 residents
Data on psychotropic
prescribing was
collected from for 139 of
150 facilities with a
response rate of 93%.
Clinical, diagnostic, and
demographic data were
not reported.
PRN: pro re nata; SD: standard deviation.
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3. Results
3.1. Description of the Selected Studies
The selected studies comprised three studies from Australia [37,43,44], one from the USA [38],
one from Norway [39], one from Canada [40], and two from Germany [41,42]. They were all published
in English except one that was in Norwegian [39]. Most studies used quantitative methods, including
cross-sectional surveys [37,39,41,42,44], a secondary analysis of a prospective cohort [40], and a
prospective longitudinal intervention study [43]. There was one qualitative study of interviews and
documentations [38].
3.2. Prevalence and Type of PRN Prescription and Administration
Variations were found in the prevalence of PRN prescription and administration, indicating
differences in routines for PRN medicines management. In addition, variations in reporting PRN
medications in terms of percentages and means hindered comparison of the studies’ findings and
derivation of a single overall figure. Prevalence ranged from 1.1% of prescriptions [39] to 35.9%
of prescriptions [42], depending on residents’ underlying conditions. Additionally, a few studies
provided data on the actual administration of prescribed PRN medications, rather than prescriptions.
Medicines prescribed and administered PRN to residents in long-term care settings included anxiolytics,
hypnotics, and antipsychotics under different names and brands (Table 3).
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Table 3. Prevalence and type of PRN prescription and administration.
Authors/Year Prevalence of PRN Prescription Prevalence of PRN Administration Medicines Prescribed or Administered PRN
Snowdon et al., 2011 [37]
Mean number of 1.3 per resident
Mean number of 0.9 when topical applications
such as ear, eye, nose, and dermatological
preparations were excluded (no measures of
dispersion reported.)
Once or more in every 5 prescriptions
Clonazepam and midazolam for six residents and
antipsychotic and/or anxiolytic medications
including haloperidol to 3.3% of residents and
Risperidone to 1%. Numerators and denominators
were not reported.
Carder, 2012 [38]
Nearly all residents had a PRN order, with a
range from 0 to 14 per resident, and with a
mean of 5.82 (no measures of
dispersion reported.)
No data No data
Rønningen et al., 2013 [39] 1.1% (n = 183) of prescriptions 519 of the 839 (61.9%)
Psychotropic medications such as oxazepam,
clomethiazole, diazepam, zopiclone, tramadol,
morphine, and oxycodone were among the most
frequently prescribed and administered medications
as different brand names or pharmaceutical
formulations (e.g., tablets and suppositories).
Percentages, numerators, and denominators were
not reported.
Voyer et al., 2015 [40] 19.9% of prescriptions No data
Antipsychotics including risperidone (37.9%),
haloperidol (34.5%), quetiapine (10.3%), olanzapine
(10.3%), haloperidol, and quetiapine (3.4%) were
prescribed. After 5 months, olanzapine was
replaced by risperidone (3.4%). Numerators and
denominators were not reported.
Dörks et al., 2016 [41]
A total of 2117 (27.9 %) prescriptions were
PRN. Additionally, 638 (74.9 %) received at
least one PRN medication. Each resident was
treated with a mean of 2.5 ± 2.3 PRN
medications.
No data Lorazepam was prescribed to 67 (7.9%) of residentswith a mean duration of 579 ± 627 days.
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Table 3. Cont.
Authors/Year Prevalence of PRN Prescription Prevalence of PRN Administration Medicines Prescribed or Administered PRN
Allers et al., 2017 [42]
A percentage of 35.9% of prescriptions to
residents with dementia vs. 23.0% for those
without dementia were PRN.
No data
23.8% of residents with dementia and 5.7% without
dementia were prescribed PRN antipsychotics. Only
a small percentage of residents without dementia
received PRN antipsychotics alone, without any
scheduled antipsychotic medications (3.1%), a lower
proportion than residents with dementia (10.8%).
Residents with dementia were prescribed both
scheduled and PRN antipsychotics more often than
residents without dementia (13.0 vs. 2.5%). Of
typical antipsychotics, melperone and promethazine
were most often prescribed. Numerators and
denominators were not reported.
Westbury et al., 2018 [43]
PRN antipsychotics were prescribed to 10.8%
(9.5-12.1%) and benzodiazepines to 30.1%
(27.6-32.6%) of residents.
No data
Antipsychotics, excluding lithium and
prochlorperazine, and all types of benzodiazepines
were converted to diazepam equivalents, but no
separate data on each medication were provided.
Westbury et al., 2019 [44]
Of 11368 residents, 1261 (11.1%) and 3461
(30.5%) were prescribed PRN antipsychotics
and PRN benzodiazepines, respectively.
No data
A percentage of 11.1% of residents were prescribed
PRN atypical antipsychotics, including risperidone,
quetiapine, and olanzapine, and typical
antipsychotics such as haloperidol. Benzodiazepine,
as an anxiolytic, prescribing included oxazepam,
diazepam, and alprazolam to 17.9% of residents.
Hypnotics, temazepam, and nitrazepam were
prescribed to 16.4%. Both regular and PRN
benzodiazepines were prescribed to 1150 residents
(47%). Additionally, 724 (29%) of them with regular
antipsychotic orders were prescribed extra
doses of PRN.
PRN: pro re nata.
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3.3. Factors Affecting PRN Medicines Management
PRN prescription and administration was associated with residents’ behaviours and needs,
including seeking attention and disturbing others during the night [38,40]. Decisions to administer PRN
medications were informed by residents’ verbal requests, nonverbal cues, interpretation of residents’
behaviours, and the settings’ characteristics in terms of staffing pattern, storage and documentation of
medications, and circumstances for use, discontinuation, and reporting [38]. Education, experience, and
interdisciplinary interventions improved antipsychotic and benzodiazepine medicines management
in terms of reduction of overall PRN prescription and administration [43]. While demographic
characteristics of residents in terms of age and gender were not associated with PRN prescription and
administration, higher numbers of PRN medications were associated with increased use of long-term
medications (7.4 ± 3.5) and a longer duration of stay (4.8 ± 4.3 years). Dementia diagnosis and older
age were associated with more PRN medication prescription and administration [41,42]. Additionally,
a longer stay, above the median of 2.1 years, was associated with 2.38 more PRN medications [41].
4. Discussion
In this review, the prevalence of PRN prescribing in long-term care settings is varied. Variations
were observed in PRN medicines management in terms of the type of medications prescribed and
administered, residents’ underlying health conditions and needs, and the length of stay. However,
differences in the studies’ methods and paucity of description of contextual factors affecting PRN
processes make it difficult to compare findings and identify common patterns for PRN prescription
and administration. Our review also showed variations in the type of psychotropic PRN medications
prescribed. Such variation could be attributed to differences in medicines management routines,
clinical reasoning, and personal judgments [1].
There were no reports as to the reasons underlying why PRN medications were prescribed and
administered, but the absence of guidelines, and information as to the side effects and adverse drug
reactions and “what to look out for” was notable. The use of unnecessary medications, excess dosing,
and lack of monitoring in terms of medications’ effects and side effects have been highlighted as the most
frequent medication-related problems, particularly for psychotropic medications [27,45]. Appropriate
medication prescription for residents living in long-term care settings is a challenge for healthcare
systems across the globe. It often increases the risk of adverse drug reactions (ADRs) and polypharmacy.
Since many ADRs are preventable, some screening tools have been devised, including Beers’ Criteria
and the Inappropriate Prescribing in the Elderly Tool (IPET), which augment professionals’ clinical
judgement in medicine selection and prescription [46]. Profiling the adverse effects of psychotropic
medications detects any changes in the patient following PRN administration [47,48]. Additionally,
medicine reviews and checks for drug interactions, cautions, and doses have been suggested, including
the Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP) [27,49], the
Screening Tool to Alert to Right Treatment (START) [49,50] for older people, and the Norwegian
General Practice (NORGEP) tool [51] for those under 71 years. However, PRN medicines management
has not been incorporated into the above-mentioned monitoring tools.
The interpretation of behavioural and other symptoms in residents and prediction of residents’
needs were mentioned as factors influencing how PRN medications were handled. However, in
general, behaviours indicating the need for PRN medication administration were not clearly and
specifically described. Additionally, it is unclear whether PRN administration is commenced by
the nurse, the resident, or the family [52]. Prescription and administration of PRN psychotropic
medications should not expose patients to the feelings of inferiority and coercion [3]. Since the
decision-making process regarding PRN management is complex [11,12], there is a need for a decision
support tool for PRN medicines management to prevent medication-related harm in long-term care
settings: this should encompass systematic checks for the signs and symptoms of ADRs [47,48].
This review highlights the effect of a healthcare setting’s routines, and the education and training
on how to handle PRN psychotropic medications’ administration and prescription. This is a general
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mandate for healthcare systems to devise and implement comprehensive national medicine policies
to ensure safe and reliable medication prescription and administration [53], and to balance the
risk and benefits of medications among residents [54]. However, there are often inconsistencies
between prescription notes and administration records, which can overshadow attempts to assess
the effectiveness of PRNs, due to a lack of data on the effect of PRNs on patients’ outcomes [52]. For
example, there are different perceptions and opinions amongst physicians that prescribe, and nurses
that administer, PRN medication [4,55]. Additionally, there are controversies regarding the use of
PRN medications and non-pharmacological strategies including counselling, distraction, verbal and
non-verbal de-escalation, massage, and education [4,5,29,56,57]. The improvement of PRN prescription
practice and promotion of PRN prescription and administration requires changes in the healthcare
policies of patient safety in care homes [27,58,59], including the mandate of formalised, systematic
checking of residents for potential ADRs [47,48]. The implementation of system-level standards of
practice for PRN administration, impact assessment, and documentation can help to improve overall
patient safety in care homes [52]. Accountability for the administration of PRN medications can be
improved by educating nurses in terms of vigilance over indications, reasons for use, medication
effects and side effects, regular checking of prescribed medications, and continuous monitoring so as
to avoid high dose medication and polypharmacy to ensure efficacy and prevent harm [9,60–63].
5. Conclusions
This systematic review focused on the PRN prescription and administration of psychotropic
medications in long-term care settings. It used an integrative design, including both qualitative and
quantitative research, to provide a more comprehensive overview of PRN and factors influencing
it in practice. There is little information regarding the reasons underlying PRN deployment, and
how related side effects and adverse reactions are identified and managed. Additionally, variations
in the prevalence of PRN prescription and administration across long-term care settings indicate
the absence of an appropriate and unified framework to be followed by all staff in the process of
PRN medicines management. Accordingly, this review has identified a need to improve medicines
management by exploring factors affecting PRN prescription and administration and by developing
appropriate guidelines to prevent harm and to improve the quality and safety care delivered to
those who live in long-term care facilities. This review has offered broader insights into healthcare
provision, particularly nurses’ roles in monitoring patients and making decisions within collaborative
environments of healthcare systems. This review has established the prevalence of PRN prescription
and administration. Intervention studies, with qualitative components, are now needed to explore
how healthcare providers and nurses can participate in daily care decisions about PRN medication
prescription and administration and can monitor effects on residents’ health and wellbeing.
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